Stay updated on Doxorubicin-Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Doxorubicin-Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial page.

Latest updates to the Doxorubicin-Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial page
- Check6 days agoChange DetectedRevision: v3.3.4 was added and Revision: v3.3.3 was removed; no study details, enrollment, or eligibility information appear to be changed; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check13 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedA Locations section with a Washington entry has been added, improving visibility of where the study is conducted. The previous 'Washington Locations' entry and the HHS Vulnerability Disclosure have been removed.SummaryDifference0.2%

- Check57 days agoChange DetectedPublications description updated to indicate that items are automatically filled from PubMed and may not be about the study, and the Revision label changed from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check64 days agoChange DetectedRemoved the funding/operating status notice from the page. The study details and related information remain unchanged.SummaryDifference0.3%

- Check78 days agoChange DetectedBoth screenshots show the same page sections and information for Study NCT03331341; no additions or deletions are evident.SummaryDifference0.4%

- Check107 days agoChange Detected- Added a government funding notice and operating status guidance, plus a pointer to cc.nih.gov; - Bumped version from v3.1.0 to v3.2.0.SummaryDifference3%

Stay in the know with updates to Doxorubicin-Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Doxorubicin-Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial page.